Hyzaar 100/12.5 MSD

£75.00

Hyzaar 100/12.5 MSD is a dual-component hypertension research formulation combining 100mg losartan potassium with 12.5mg hydrochlorothiazide, providing comprehensive angiotensin II receptor antagonism alongside diuretic mechanisms for cardiovascular pharmacology investigations.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Hyzaar 100/12.5 MSD
Hyzaar 100/12.5 MSD
£75.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Compound Profile: Hyzaar 100/12.5 MSD

Hyzaar 100/12.5 MSD is a dual-component pharmaceutical formulation combining 100mg losartan potassium with 12.5mg hydrochlorothiazide, developed by MSD for cardiovascular pharmacology research. This fixed-dose combination represents a sophisticated approach to investigating dual-mechanism blood pressure regulation, utilising both angiotensin II receptor blockade and thiazide diuretic pathways. Research laboratories examining antihypertensive mechanisms frequently study this combination for its synergistic effects on renin-angiotensin-aldosterone system modulation and fluid balance regulation.

The formulation’s dual-action profile enables researchers to investigate combined therapeutic approaches in cardiovascular disease models. When sourcing from Stroid UK Shop, research facilities gain access to pharmaceutical-grade compounds essential for hypertension studies. This combination therapy model provides valuable insights into multi-target pharmacological interventions.

Research Applications

Cardiovascular research laboratories utilise Hyzaar formulations to investigate antihypertensive mechanisms across multiple physiological pathways. The losartan component enables examination of angiotensin II receptor type 1 (AT1) antagonism, while hydrochlorothiazide facilitates study of thiazide-type diuretic effects on sodium-chloride cotransporter inhibition. Research applications span from basic cardiovascular physiology studies to complex pharmacokinetic interaction analyses.

Clinical pharmacology research benefits significantly from investigating this established pharmaceutical combination. Studies examining dose-response relationships, drug interaction profiles, and comparative efficacy assessments frequently incorporate this formulation. Researchers examining other drugs alongside established antihypertensive compounds can evaluate comprehensive treatment protocols. Additionally, laboratories studying SARMs or peptides may investigate potential cardiovascular interactions with established pharmaceutical agents.

Specifications

Hyzaar 100/12.5 MSD Technical Specifications
Parameter Specification
Active Components Losartan potassium 100mg + Hydrochlorothiazide 12.5mg
Manufacturer MSD (Merck Sharp & Dohme)
Formulation Fixed-dose combination tablet
Losartan CAS 124750-99-8
HCTZ CAS 58-93-5
Storage Requirements Room temperature, dry conditions

Research Compliance

This pharmaceutical combination is supplied exclusively for in-vitro laboratory research and analytical reference purposes. Hyzaar 100/12.5 MSD is intended for qualified research institutions conducting cardiovascular pharmacology studies, drug interaction analyses, or pharmaceutical development research. This product is not intended for human consumption, therapeutic use, or any applications outside controlled laboratory environments. Researchers must ensure compliance with institutional protocols and regulatory requirements governing pharmaceutical research compounds.

Related